Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2010 Apr 9

PMID 20375999

Citations 96

Authors

P Lenzini

M Wadelius

S Kimmel

J L Anderson

A L Jorgensen

M Pirmohamed

M D Caldwell

N Limdi

J K Burmester

M B Dowd

P Angchaisuksiri

A R Bass

J Chen

N Eriksson

A Rane

J D Lindh

J F Carlquist

B D Horne

G Grice

P E Milligan

C Eby

J Shin

H Kim

D Kurnik

C M Stein

G McMillin

R C Pendleton

R L Berg

P Deloukas

B F Gage

Affiliations

Soon will be listed here.

Abstract

Well-characterized genes that affect warfarin metabolism (cytochrome P450 (CYP) 2C9) and sensitivity (vitamin K epoxide reductase complex 1 (VKORC1)) explain one-third of the variability in therapeutic dose before the international normalized ratio (INR) is measured. To determine genotypic relevance after INR becomes available, we derived clinical and pharmacogenetic refinement algorithms on the basis of INR values (on day 4 or 5 of therapy), clinical factors, and genotype. After adjusting for INR, CYP2C9 and VKORC1 genotypes remained significant predictors (P < 0.001) of warfarin dose. The clinical algorithm had an R(2) of 48% (median absolute error (MAE): 7.0 mg/week) and the pharmacogenetic algorithm had an R(2) of 63% (MAE: 5.5 mg/week) in the derivation set (N = 969). In independent validation sets, the R(2) was 26-43% with the clinical algorithm and 42-58% when genotype was added (P = 0.002). After several days of therapy, a pharmacogenetic algorithm estimates the therapeutic warfarin dose more accurately than one using clinical factors and INR response alone.

Citing Articles

Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation.

Shi K, Deng J Pharmacogenet Genomics. 2024; 34(9):275-284.

PMID: 39356590 PMC: 11424055. DOI: 10.1097/FPC.0000000000000545.

Construction of warfarin population pharmacokinetics and pharmacodynamics model in Han population based on Bayesian method.

Xia X, Cai X, Chen J, Jiang S, Zhang J Sci Rep. 2024; 14(1):14846.

PMID: 38937509 PMC: 11211351. DOI: 10.1038/s41598-024-65048-7.

Application of a warfarin dosing calculator to guide individualized dosing empirical adjustment after fixed dosing: a pilot study.

Cai X, Chen J, Chen M, Xia X, Fang G, Zhang J Front Pharmacol. 2023; 14:1235331.

PMID: 37663245 PMC: 10469691. DOI: 10.3389/fphar.2023.1235331.

Validation and comparison between two warfarin dosing clinical algorithms and warfarin fixed dosing in specialized heart center: cross-sectional study.

Elnour A, Ahmed I, Khalid A, Elmustafa M Pharm Pract (Granada). 2023; 20(3):2722.

PMID: 36733524 PMC: 9851814. DOI: 10.18549/PharmPract.2022.3.2722.

Long Short-Term Memory Network for Development and Simulation of Warfarin Dosing Model Based on Time Series Anticoagulant Data.

Kuang Y, Liu Y, Pei Q, Ning X, Zou Y, Liu L Front Cardiovasc Med. 2022; 9:881111.

PMID: 35647078 PMC: 9130657. DOI: 10.3389/fcvm.2022.881111.

References

Gage B, Eby C, E Milligan P, Banet G, Duncan J, McLeod H . Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2003; 91(1):87-94. DOI: 10.1160/TH03-06-0379. View

Wu A . Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics. 2008; 8(7):851-61. DOI: 10.2217/14622416.8.7.851. View

Budnitz D, Pollock D, Weidenbach K, Mendelsohn A, Schroeder T, Annest J . National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006; 296(15):1858-66. DOI: 10.1001/jama.296.15.1858. View

Harrison L, Johnston M, Massicotte M, Crowther M, Moffat K, Hirsh J . Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997; 126(2):133-6. DOI: 10.7326/0003-4819-126-2-199701150-00006. View

Ageno W, Turpie A . Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol. 1999; 84(8):905-8. DOI: 10.1016/s0002-9149(99)00463-4. View

Limdi N, Beasley T, Crowley M, Goldstein J, Rieder M, Flockhart D . VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008; 9(10):1445-58. PMC: 2586955. DOI: 10.2217/14622416.9.10.1445. View

DAndrea G, DAmbrosio R, Di Perna P, Chetta M, Santacroce R, Brancaccio V . A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2004; 105(2):645-9. DOI: 10.1182/blood-2004-06-2111. View

Higashi M, Veenstra D, Kondo L, Wittkowsky A, Srinouanprachanh S, Farin F . Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287(13):1690-8. DOI: 10.1001/jama.287.13.1690. View

Kovacs M, Rodger M, Anderson D, Morrow B, Kells G, Kovacs J . Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med. 2003; 138(9):714-9. DOI: 10.7326/0003-4819-138-9-200305060-00007. View

10.

Wysowski D, Nourjah P, Swartz L . Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007; 167(13):1414-9. DOI: 10.1001/archinte.167.13.1414. View

11.

Limdi N, McGwin G, Goldstein J, Beasley T, Arnett D, Adler B . Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2007; 83(2):312-21. PMC: 2683398. DOI: 10.1038/sj.clpt.6100290. View

12.

Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue Q, Magnusson P . Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 2003; 4(1):40-8. DOI: 10.1038/sj.tpj.6500220. View

13.

Pirmohamed M . Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006; 62(5):509-11. PMC: 1885167. DOI: 10.1111/j.1365-2125.2006.02806.x. View

14.

Solomon H, Randall J, SIMMONS V . Heparin-induced increase in the international normalized ratio. Responses of 10 commercial thromboplastin reagents. Am J Clin Pathol. 1995; 103(6):735-9. DOI: 10.1093/ajcp/103.6.735. View

15.

Caldwell M, Awad T, Johnson J, Gage B, Falkowski M, Gardina P . CYP4F2 genetic variant alters required warfarin dose. Blood. 2008; 111(8):4106-12. PMC: 2288721. DOI: 10.1182/blood-2007-11-122010. View

16.

Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahe I . Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med. 2005; 118(2):137-42. DOI: 10.1016/j.amjmed.2004.07.053. View

17.

Margaglione M, Colaizzo D, DAndrea G, Brancaccio V, Ciampa A, Grandone E . Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000; 84(5):775-8. View

18.

Wang D, Chen H, Momary K, Cavallari L, Johnson J, Sadee W . Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008; 112(4):1013-21. PMC: 2515137. DOI: 10.1182/blood-2008-03-144899. View

19.

Holbrook A, Pereira J, Labiris R, McDonald H, Douketis J, Crowther M . Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165(10):1095-106. DOI: 10.1001/archinte.165.10.1095. View

20.

McClain M, Palomaki G, Piper M, Haddow J . A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. 2008; 10(2):89-98. DOI: 10.1097/GIM.0b013e31815bf924. View